Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Colorcon
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR ZIDOVUDINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Zidovudine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000590 ↗ Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000590 ↗ Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000590 ↗ Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000625 ↗ A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 Completed Bristol-Myers Squibb Phase 2 1969-12-31 To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
NCT00000625 ↗ A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 Completed Glaxo Wellcome Phase 2 1969-12-31 To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zidovudine

Condition Name

Condition Name for Zidovudine
Intervention Trials
HIV Infections 414
HIV 31
Pregnancy 21
HIV Infection 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zidovudine
Intervention Trials
HIV Infections 451
Acquired Immunodeficiency Syndrome 126
Infections 119
Infection 105
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zidovudine

Trials by Country

Trials by Country for Zidovudine
Location Trials
Puerto Rico 89
Thailand 71
Canada 58
Spain 36
South Africa 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zidovudine
Location Trials
California 239
New York 209
Florida 163
Illinois 149
Massachusetts 146
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zidovudine

Clinical Trial Phase

Clinical Trial Phase for Zidovudine
Clinical Trial Phase Trials
Phase 4 52
Phase 3 98
Phase 2/Phase 3 10
[disabled in preview] 142
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zidovudine
Clinical Trial Phase Trials
Completed 465
Unknown status 19
Terminated 18
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zidovudine

Sponsor Name

Sponsor Name for Zidovudine
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 246
Glaxo Wellcome 68
Bristol-Myers Squibb 38
[disabled in preview] 65
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zidovudine
Sponsor Trials
NIH 309
Industry 308
Other 250
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Harvard Business School
Dow
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.